At the ASCO congress in Chicago 2026, preliminary data from a new therapeutic approach show a significant increase in survival in pancreatic cancer. A result welcomed by long applause from the scientific community.
The long applause was not immediate. It started almost quietly, as happens when something takes a few seconds to really understand in a room full of oncologists. Then the curves on the screen, the survival numbers and the sudden silence gave way to a rare reaction in scientific conferences: the audienceASCO of Chicagothe annual congress ofAmerican Society of Clinical Oncologythe most important global event in oncology, where the main results of research on new drugs and therapies are presented which every year brings together thousands of specialists from all over the world, has risen standing to applaud for a very long standing ovation. The protagonist of the presentation was daraxonrasiba new oral drug designed to target one of the most widespread and so far most difficult to treat genetic alterations in pancreatic cancerthe mutation of KRAS. The data that caught attention is simple to state but complex to interpret: in patients with already treated metastatic disease, the median survival was approximately double compared to standard chemotherapy.
A tumor that is still among the most aggressive, where even a few months make the difference
The pancreatic cancer it remains one of the most difficult tumors to deal with in oncology. The diagnosis often comes late, when the disease has already developed metastases or is no longer operable. Also for this reason, in recent decades, progress has been slower than in other solid tumors. The therapies available to date, based mainly on combined chemotherapyimproved survival only gradually. In this context, even a gain of a few months is not a statistical detail, but a clinically relevant result. It is against this background that the data presented at ASCO take on a particular meaning.
The Chicago trial: what the new drug really showed
The study presented at the congress, known as RASolute 302involved approximately 500 patients with metastatic pancreatic adenocarcinoma already subjected to a first line of treatment. It is therefore a difficult population, terminal patients with advanced disease and few therapeutic options available. The patients were treated with the new drug, daraxonrasibor with standard chemotherapy used in the second line. The main objective was to measure overall survival, that is, the overall life time after starting treatment. The result that struck the scientific community was a significant increase in average survival: from about six and a half months with standard therapy to just over a year with the new drug. In pancreatic oncology, where margins for improvement are historically limited, this data has been interpreted as a strong signal.
A “historic” biological target finally hit
The reason for the interest in daraxonrasib is not just the clinical outcome, but its target. The drug actually acts on KRASone of the most frequent mutations in pancreatic cancer. For years this genetic alteration was considered almost impossible to target with drugs, so much so that it was defined in the past a sort of “invisible target” of oncology. In recent years, research has begun to change this perspective, but concrete clinical results were still limited. The data presented in Chicago suggests instead that intervening directly on this mechanism can result in a real benefit for patients. Alongside the increase in survival, the researchers also highlighted another element: the tolerability of the treatment. Although it is an active therapy, the side effect profile appeared more manageable than chemotherapy traditional, a crucial aspect in an often fragile population.
Between enthusiasm and caution: what happens now
Despite the enthusiasm that emerged in the room, oncologists urge caution. The data comes from a conference presentation and will need to be confirmed by complete publications and longer follow-up. The history of pancreatic cancer in fact, it teaches that initially promising results can diminish over time. However, one point remains that is difficult to ignore: for the first time, a drug directed against KRAS shows such a clear impact on survival in this disease. Not a definitive revolution, but a signal that the biology of pancreatic cancer can finally be addressed more effectively. And this is probably the reason for that long applause in Chicago. Not only for the data itself, but for what it represents: the concrete possibility that one of the most difficult tumors in modern oncology is slowly starting to change history.
